Our overall results confirm a correlation between reduced GAS5 expression and poor clinical outcomes, and reveal an association with increased likelihood of lymph node metastasis (LNM) and distant metastasis (DM) in patients with early stage tumors. Here, GAS5 is linked to metastatic malignant neoplasm in the lymph nodes.